Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Minal Mehta"'
Autor:
Sai-Hong Ignatius Ou, MD, Huamao M. Lin, PhD, MBA, Jin-Liern Hong, PhD, Yu Yin, MS, MPH, Shu Jin, MS, Jianchang Lin, PhD, Minal Mehta, MBBS, Danny Nguyen, MD, Joel W. Neal, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 10, Pp 100558- (2023)
Introduction: This study describes treatment patterns and outcomes in patients with NSCLC with EGFR exon 20 insertions (EGFRex20ins) in the United States. Methods: The Flatiron Health electronic health record database was used to select three cohorts
Externí odkaz:
https://doaj.org/article/a85d4cc4ba7e4e79b72ec1af541ad695
Autor:
James Chih-Hsin Yang, Caicun Zhou, Pasi A. Jänne, Suresh S. Ramalingam, Tae Min Kim, Gregory J Riely, Alexander I Spira, Zofia Piotrowska, Tarek Mekhail, Maria Rosario Garcia Campelo, Enriqueta Felip, Lyudmila Bazhenova, Shu Jin, Manmit Kaur, Paul M. Diderichsen, Neeraj Gupta, Veronica Bunn, Jianchang Lin, Eric N. Churchill, Minal Mehta, Danny Nguyen
Publikováno v:
Scientia
Carcinoma; Càncer de pulmó de cèl·lules no petites; Seguretat del pacient Carcinoma; Cáncer de pulmón de células no pequeñas; Seguridad del paciente Carcinoma; Non–small cell lung cancer; Patient safety Background Mobocertinib has demonstra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecb5aba9fc993a8a81cdb148cab84a27
https://hdl.handle.net/11351/9519
https://hdl.handle.net/11351/9519
Autor:
Maria Rosario, Garcia Campelo, Caicun, Zhou, Suresh S, Ramalingam, Huamao M, Lin, Tae Min, Kim, Gregory J, Riely, Tarek, Mekhail, Danny, Nguyen, Erin, Goodman, Minal, Mehta, Sanjay, Popat, Pasi A, Jänne
Publikováno v:
Journal of clinical medicine. 12(1)
Mobocertinib, an oral, first-in-class epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor selective for
Autor:
Sai-Hong I. Ou, Huamao M. Lin, Jin-Liern Hong, Yu Yin, Shu Jin, Jianchang Lin, Minal Mehta, Pingkuan Zhang, Danny Nguyen, Joel W. Neal
Publikováno v:
Lung Cancer. 179:107186
Autor:
Neeraj Gupta, Anna Largajolli, Han Witjes, Paul M. Diderichsen, Steven Zhang, Michael J. Hanley, Jianchang Lin, Minal Mehta
Publikováno v:
Clinical pharmacology and therapeutics. 112(2)
Mobocertinib is an oral tyrosine kinase inhibitor approved for treatment of patients with locally advanced or metastatic non-small cell lung cancer (mNSCLC) with epidermal growth factor receptor gene (EGFR) exon 20 insertion (ex20ins) mutations previ